Followers | 46 |
Posts | 4449 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
Sunday, March 29, 2020 12:00:21 PM
Dave Pearson | March 25, 2020 | Healthcare Innovation
Two data scientists say they’ve created AI algorithms that can do in a week what biological researchers might otherwise spend years trying to pull off in a laboratory: discover antibody-based treatments that have a fighting chance to beat back COVID-19.
In fact, studies have shown it takes an average of five years and half a billion dollars to find and fine-tune antibodies in a lab, Andrew Satz and Brett Averso, both execs of a 12-member startup called EVQLV, explain.
Speaking with their alma mater, Columbia University’s Data Science Institute, Satz and Averso say their machine-learning algorithms can help by cutting the chances of costly experimental failures in the lab.
“We fail in the computer as much as possible to reduce the possibility of downstream failure in the laboratory,” Satz tells the institute’s news division. “[T]hat shaves a significant amount of time from laborious and time-consuming work.”
EVQLV is working on the advancement with Immunoprecise Antibodies (IPA), a bioscience research company concentrating on discovering therapeutic antibodies.
The collaboration “will accelerate the effort to develop therapeutic candidates against COVID-19,” according to the news report. “EVQLV will identify and screen hundreds of millions of potential antibody treatments in only a few days—far beyond the capacity of any laboratory.”
With the algorithmic screening complete, IPA will produce and test the most promising antibody candidates, the school reports.
“Speeding up the first stage of the process—antibody discovery—goes a long way toward expediting the discovery of a treatment for COVID-19.”
https://www.aiin.healthcare/topics/healthcare-innovation/machine-learning-teams-antibody-science-covid-19-treatment-discovery
Recent IPA News
- InterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IA • Business Wire • 03/28/2024 06:35:00 PM
- InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications • Business Wire • 03/28/2024 11:02:00 AM
- IPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IA • Business Wire • 03/20/2024 05:52:00 PM
- IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments • Business Wire • 03/20/2024 11:02:00 AM
- IPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024* • Business Wire • 03/14/2024 11:39:00 PM
- IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024* • Business Wire • 03/14/2024 12:05:00 PM
- BioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFT • Business Wire • 03/07/2024 08:24:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 04:19:01 PM
- IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology • Business Wire • 03/07/2024 12:02:00 PM
- L'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024 • Business Wire • 03/04/2024 09:50:00 PM
- IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024 • Business Wire • 03/04/2024 01:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2024 10:29:18 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/23/2024 10:26:04 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 02/15/2024 08:12:47 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 06:53:08 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/10/2024 06:33:21 PM
- IPA présente ses résultats financiers et les récents points forts de son activité pour le deuxième trimestre de l’exercice 2024* • Business Wire • 12/14/2023 08:08:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 01:48:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 01:38:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 01:03:16 PM
- IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024* • Business Wire • 12/14/2023 01:01:00 PM
- IPA annonce la clôture d'une offre publique d'actions ordinaires pour un montant de 1 265 million de dollars • Business Wire • 12/09/2023 02:57:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/08/2023 10:11:10 PM
- IPA Announces Closing of $1.265 Million Public Offering of Common Shares • Business Wire • 12/08/2023 10:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/07/2023 09:53:47 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM